Searched for
SUN PHARMA CIPLA
Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Sun Pharma, Cipla or Dr Reddy's: Which pharma major is most vulnerable to Trump's 100% tariffPresident Trump's imposition of 100% tariffs on branded drugs has shaken Indian pharma companies, impacting stocks like Sun Pharma, Cipla, ...
- Sun Pharma, Cipla enter licensing agreement with Takeda to market novel gastrointestinal drug in IndiaSun Pharma and Cipla have entered a licensing deal with Takeda Pharmaceutical to commercialize Vonoprazan tablets in India. This novel drug...
- Pharma largecaps doing well, 3 stocks to bet on: Rahul ShahRahul Shah, VP-Equity Advisory, MOFSL, says most of the IT names have gone up quite sharply post their Q3 numbers. Now it is the turn of ph...
- Outlook on healthcare sector; Cipla & Sun Pharma could give 15-20% returnANDA approval rate has been on a steady rise post-COVID, from the low of 540 in CY21 to ~700+ annual approvals in CY23E, backed by a reduct...
- Nithya Balasubramanian's top 3 pharma stock picks"When it comes to Sun Pharma, I think their commercial muscle in India is under-appreciated."
- Cipla and Ranbaxy can appreciate 20% from current price levels: Deven ChokseyCipla and Ranbaxy hold reasonably good chance of appreciating around 20% to 30% from current market price levels.
- Delhi HC extends relief period for pharma cos in drug pricing caseOther companies that have approached the court include Micro Labs, Lupin, Wockhardt, Intas Pharma, Alembic Pharma and Emcure Pharma.
- Sun Pharma, Cipla already been re-rated a lot: P Phani SekharThey have already been re-rated a lot so I guess there is little scope at least in the longer term perspective for that to happen
- Sun Pharma, Cipla will continue to grow: Vivek Mavani, Market AnalystI would even look at midcap within the pharma space, Ajanta Pharma, pure domestic focussed company, says Vivek Mavani.
- Cipla, Ranbaxy to outperform pharma space: KR Choksey SecOne will have to look at Cipla and Ranbaxy as the potential candidate for outperformance in the pharma space in coming year.
- Pharmas are quite divided: Deepak Mohoni"Pharmas are quite divided. There are two very strong pharmas at the moment. They are Sun Pharma and Cipla. They are making all the moves."
Load More
